Redox-Responsive Disulfide Cyclic Peptides: A New Strategy for siRNA Delivery.
STAT3
cyclic peptide
protein silencing
siRNA
triple-negative breast cancer
Journal
Molecular pharmaceutics
ISSN: 1543-8392
Titre abrégé: Mol Pharm
Pays: United States
ID NLM: 101197791
Informations de publication
Date de publication:
02 05 2022
02 05 2022
Historique:
pubmed:
30
3
2022
medline:
4
5
2022
entrez:
29
3
2022
Statut:
ppublish
Résumé
RNA interference (RNAi) is a powerful tool capable of targeting virtually any protein without time-consuming and expensive drug development studies. However, due to obstacles facing efficient and safe delivery, RNAi-based therapeutic approach remains a challenge. Herein, we have designed and synthesized a number of disulfide-constraining cyclic and hybrid peptides using tryptophan and arginine residues. Our hypothesis was that peptide structures would undergo reduction by intracellular glutathione (more abundant in cancer cells) and unpack the small interfering RNA (siRNA) from the peptide/siRNA complexes. A subset of newly developed peptides (specifically,
Identifiants
pubmed: 35347995
doi: 10.1021/acs.molpharmaceut.1c00879
doi:
Substances chimiques
Disulfides
0
Peptides
0
Peptides, Cyclic
0
RNA, Small Interfering
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM